We found that overexpression of EBNA2 and its targets, CCL3 and CCL4, led to doxorubicin resistance, independent of the pathway underlying LMP1-mediated protection of cancer cells against chemotherapeutic agents [24–28]. The gene discussed is CCL3; the disease is cancer.